All Categories
| | 
Home
What is TISSUE PLASMINOGEN ACTIVATOR, HUMAN
**Introduction to Tissue Plasminogen Activator, Human (tPA)** Tissue Plasminogen Activator, Human (tPA), is a vital thrombolytic enzyme used clinically to dissolve blood clots in conditions like acute ischemic stroke, myocardial infarction, and pulmonary embolism. As a serine protease, tPA converts plasminogen into plasmin, breaking down fibrin clots and restoring blood flow. Derived through recombinant DNA technology, human tPA offers high specificity for fibrin-bound clots, minimizing systemic bleeding risks. Its rapid action is critical in time-sensitive emergencies, improving patient outcomes when administered promptly. Available in formulations like alteplase and tenecteplase, tPA remains a cornerstone of modern thrombolytic therapy, balancing efficacy with safety under strict clinical guidelines.
Preparation Process: **Preparation Method of Tissue Plasminogen Activator (tPA), Human:** 1. **Gene Cloning:** Isolate the human tPA gene and insert it into an expression vector (e.g., plasmid). 2. **Host Cell Transfection:** Introduce the vector into mammalian cells (e.g., Chinese Hamster Ovary (CHO) cells) for recombinant protein production. 3. **Cell Culture:** Grow transfected cells in bioreactors under controlled conditions (temperature, pH, nutrients). 4. **Protein Expression:** Induce tPA synthesis and secrete it into the culture medium. 5. **Harvesting:** Collect the supernatant and remove cell debris via centrifugation/filtration. 6. **Purification:** Use chromatography (affinity, ion-exchange, size-exclusion) to isolate tPA. 7. **Formulation:** Dialyze, concentrate, and stabilize tPA in a buffer (e.g., phosphate) for therapeutic use. 8. **Sterilization:** Filter through a 0.2 µm membrane for aseptic filling. 9. **Quality Control:** Test for purity, activity, and sterility before final packaging.
Usage Scenarios: Tissue Plasminogen Activator (tPA), human, is a thrombolytic agent used to dissolve blood clots in acute medical conditions. It works by converting plasminogen to plasmin, which breaks down fibrin in clots. tPA is primarily indicated for acute ischemic stroke (administered within 4.5 hours of symptom onset), myocardial infarction (to restore coronary blood flow), and pulmonary embolism (to improve lung perfusion). Its rapid action reduces tissue damage and improves outcomes. Contraindications include active bleeding, recent surgery, or hemorrhagic stroke. Adverse effects may include bleeding complications. Alteplase and tenecteplase are common recombinant forms. Strict protocols govern its use due to the risk of hemorrhage.
TISSUE PLASMINOGEN ACTIVATOR, HUMAN Basic Info
Safely Info
TISSUE PLASMINOGEN ACTIVATOR, HUMAN Price
2. China: $500 - $2,000 per dose
3. Russia: $800 - $3,000 per dose
4. Germany: $1,200 - $4,500 per dose
5. India: $300 - $1,500 per dose
6. Japan: $1,500 - $5,000 per dose
7. Brazil: $700 - $2,500 per dose
8. South Korea: $1,000 - $3,500 per dose
9. Philippines: $500 - $2,000 per dose
10. United Kingdom: $1,200 - $4,000 per dose
11. France: $1,300 - $4,200 per dose
12. Mexico: $600 - $2,200 per dose
13. Canada: $1,000 - $4,000 per dose
14. South Africa: $400 - $1,800 per dose
15. Egypt: No results
16. Turkey: $700 - $2,500 per dose
17. Thailand: $500 - $2,000 per dose
18. Indonesia: $400 - $1,800 per dose
TISSUE PLASMINOGEN ACTIVATOR, HUMAN Suppliers
Hot Recommendation
